Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
NCT04140305
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
188
Enrollment
INDUSTRY
Sponsor class
Stopped
Business objective has changed
Conditions
Multiple Sclerosis
Interventions
DRUG:
RPC-1063
Sponsor
Celgene